Table 1 Comparison of the pharmacologic... | American Society of Hematology

Table 1

Comparison of the pharmacologic properties of warfarin, rivaroxaban, apixaban, and edoxaban

	Warfarin	Dabigatran	Rivaroxaban	Apixaban	Edoxaban
Target	VKORC1	Thrombin	Factor Xa	Factor Xa	Factor Xa
Prodrug	No	Yes	No	No	No
Bioavailability (%)	100	7	80	60	62
Dosing	OD	BID	OD (BID)	BID	OD
Time-to-peak effect	4-5 d	1-3 h	2-4 h	1-2 h	1-2 h
Half-life (h)	40	14-17	7-11	8-14	5-11
Renal clearance as unchanged drug (%)	None	80	33	27	50
Monitoring	Yes	No	No	No	No
Interactions	Multiple	P-gp	3A4/P-gp	3A4/P-gp	P-gp

	Warfarin	Dabigatran	Rivaroxaban	Apixaban	Edoxaban
Target	VKORC1	Thrombin	Factor Xa	Factor Xa	Factor Xa
Prodrug	No	Yes	No	No	No
Bioavailability (%)	100	7	80	60	62
Dosing	OD	BID	OD (BID)	BID	OD
Time-to-peak effect	4-5 d	1-3 h	2-4 h	1-2 h	1-2 h
Half-life (h)	40	14-17	7-11	8-14	5-11
Renal clearance as unchanged drug (%)	None	80	33	27	50
Monitoring	Yes	No	No	No	No
Interactions	Multiple	P-gp	3A4/P-gp	3A4/P-gp	P-gp

OD, once daily; BID, twice daily; P-gp, P-glycoprotein; VKORC1, C1 subunit of the vitamin K epoxide reductase enzyme; 3A4, cytochrome P₄₅₀ 3A4 isoenzyme.

[ViewLarge]

This Feature Is Available To Subscribers Only